Pharmaceutical company Moderna on Monday said that its coronavirus vaccine showed a strong immune response in children aged between six an...
Pharmaceutical company Moderna on Monday said that its coronavirus vaccine showed a strong immune response in children aged between six and 11 in a late-stage clinical trial.
The company said that it plans to submit the data to the United States’ Food and Drug Administration, European Medicines Agency and other global regulators for approval.
In a statement, Moderna said the interim data from the trials showed that the vaccine’s safety was comparable to that seen in the clinical trials of adults. In adults, the company had said the vaccine was 94% effective.
“The majority of adverse events were mild or moderate in severity,” it said. “The most common solicited adverse events were fatigue, headache, fever, and injection site pain.”
The study, called KidCOVE, was conducted on 4,753 participants, who were divided into three groups based on their age – 6 months to less than 2 years, 6 years to less than 12 years and 2 years to less than 6 years. The results published on Monday was for the 6 years to less than 12 years age group.
It said that the vaccine showed “strong immune response in this cohort of children one month after the second dose”.
The company said it used 50 microgram shots, which is half in strength of...
